![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
http://www.pharmatimes.com/news/nice,_phe_publish_new_antimicrobial_prescribing_guideline_on_c._difficile_infection_1373497
http://www.pharmafile.com/news/583248/bial-and-medis-enter-partnership-cns-treatments
https://www.thepharmaletter.com/in-brief/brief-bial-strikes-distribution-deal-for-cee-countries?__cf_chl_jschl_tk__=pmd_f6cadfb104a45744ae1c5e2e0fe9aea42d8e9d48-1626785047-0-gqNtZGzNAmKjcnBszQiO
https://www.globenewswire.com/news-release/2021/07/01/2256457/0/en/Entasis-Therapeutics-Introduces-ETX0462-a-First-in-Class-Candidate-Targeting-Multidrug-Resistant-Gram-Negative-and-Biothreat-Pathogens.html
https://www.globenewswire.com/news-release/2021/06/30/2255713/0/en/Novome-Biotechnologies-Initiates-Phase-1-2a-Study-to-Evaluate-Therapeutically-Engineered-Bacteria-for-the-Treatment-of-Enteric-Hyperoxaluria.html
https://www.globenewswire.com/news-release/2021/06/28/2253782/35690/en/OpGen-Group-Company-Ares-Genetics-Presents-R-D-Pipeline-Updates.html
https://www.globenewswire.com/news-release/2021/06/28/2253544/0/en/Polyphor-Provides-Update-on-the-Phase-III-FORTRESS-Study-of-Balixafortide-in-Patients-With-Advanced-HER2-Negative-Breast-Cancer.html